SLFN5 and glioblastoma: SLFN5 also negatively controls STAT1-mediated transcriptional activation of IFN-stimulated genes and ZEB1 transcription, suppressing the antitumor immune response in glioblastoma cells and the mesenchymal-epithelial transition (18, 29).